Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439476 | 0.87 | LMNA (0.54) | SIGMAR1USP30GPR119MAPTMEN1 | |
| SCHEMBL27370167 | 0.86 | GPR119 (0.65) | SIGMAR1USP30GPR119MEN1KMT2A | |
| SCHEMBL30718465 | 0.86 | GPR119 (0.65) | SIGMAR1USP30GPR119MEN1KMT2A | |
| SCHEMBL29689554 | 0.86 | GPR119 (0.51) | HDAC4HDAC6USP30GPR119MEN1 | |
| SCHEMBL29689880 | 0.85 | NPC1 (0.62) | USP30GPR119EPHX2MAPTMEN1 | |
| SCHEMBL23387280 | 0.84 | SIGMAR1 (0.64) | SIGMAR1USP30EPHX2MEN1KMT2A | |
| SCHEMBL23387283 | 0.84 | SIGMAR1 (0.64) | SIGMAR1USP30EPHX2MEN1KMT2A | |
| SCHEMBL29689572 | 0.84 | SIGMAR1 (0.53) | SIGMAR1EPHX2TEAD1 | |
| SCHEMBL3642671 | 0.82 | MEN1 (0.57) | SIGMAR1GPR119EPHX2MAPTMEN1 | |
| SCHEMBL2636671 | 0.80 | MEN1 (0.57) | SIGMAR1USP30GPR119EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | SIGMAR1 732/4885HDAC4 2145/4885HDAC6 1657/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | SIGMAR1 1981/4885HDAC4 2450/4885HDAC6 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.